Clinical Trial

Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-01.
Trial Details
NCT Number NCT07512596
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia
Enrollment 48 participants
Start Date 2026-07
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-17